On July 15, Lesnar was notified of a potential anti-doping policy violation by the United States Anti-Doping Agency (USADA) stemming from an undisclosed banned substance in an out-of-competition sample collected on June 28. On July 19, a second test sample taken in-competition on July 9 was revealed as positive for the same banned substance discovered in the previous out-of-competition sample. On August 23, the Nevada State Athletic Commission (NSAC) confirmed that Lesnar had twice been tested positive for the estrogen blocker clomiphene and was suspended.